title: Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model.
abstract: Both experimental and clinical data show evidence of a correlation between elevated blood levels of carcinoembryonic antigen (CEA) and the development of liver metastases from colorectal carcinomas. However, a cause-effect relationship between these two observations has not been demonstrated. For this reason, we developed a new experimental model to evaluate the possible role of circulating CEA in the facilitation of liver metastases. A CEA-negative subclone from the human colon carcinoma cell line CO115 was transfected either with CEA-cDNA truncated at its 3' end by the deletion of 78 base pairs leading to the synthesis of a secreted form of CEA or with a full-length CEA-cDNA leading to the synthesis of the entire CEA molecule linked to the cell surface by a GPI anchor. Transfectants were selected either for their high CEA secretion (clone CO115-2C2 secreting up to 13 microg CEA per 10(6) cells within 72 h) or for their high CEA membrane expression (clone CO115-5F12 expressing up to 1 x 10(6) CEA molecules per cell). When grafted subcutaneously, CO115-2C2 cells gave rise to circulating CEA levels that were directly related to the tumour volume (from 100 to 1000 ng ml(-1) for tumours ranging from 100 to 1000 mm3), whereas no circulating CEA was detectable in CO115 and CO115-5F12 tumour-bearing mice. Three series of nude mice bearing a subcutaneous xenograft from either clone CO115-2C2 or the CO115-5F12 transfectant, or an untransfected CO115 xenograft, were further challenged for induction of experimental liver metastases by intrasplenic injection of three different CEA-expressing human colorectal carcinoma cell lines (LoVo, LS174T or CO112). The number and size of the liver metastases were shown to be independent of the circulating CEA levels induced by the subcutaneous CEA secreting clone (CO115-2C2), but they were directly related to the metastatic properties of the intrasplenically injected tumour cells.
authors.affiliation: Centre de Recherche en Cancérologie, CRLC Val d'Aurelle--Paul Lamarque Cancer Centre, Parc Euromédecine, Montpellier, France.
authors.forename: A
authors.initials: A
authors.lastname: Leconte
authors.forename: V
authors.initials: V
authors.lastname: Garambois
authors.forename: M
authors.initials: M
authors.lastname: Ychou
authors.forename: B
authors.initials: B
authors.lastname: Robert
authors.forename: D
authors.initials: D
authors.lastname: Pourquier
authors.forename: A
authors.initials: A
authors.lastname: Terskikh
authors.forename: J P
authors.initials: JP
authors.lastname: Mach
authors.forename: A
authors.initials: A
authors.lastname: Pèlegrin
mesh_terms: D000818:Animals; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000502:physiology*; D015179:Colorectal Neoplasms / Q000097:blood / Q000473:pathology*; D005260:Female; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000556:secondary*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D002272:Carcinoembryonic Antigen